secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001600620-25-000047
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q1 revenue $62.5M (+24% YoY); net income $23.3M vs loss of $10.7M; LUPKYNIS sales up 25%
--------------------------------------------------------------------------------

- Total revenue $62.5M, up 24% YoY; net product sales of LUPKYNIS were $60.0M (+25% YoY).
- Net income $23.3M vs net loss $(10.7)M in Q1 2024; cash flow from operations $1.3M ($12.4M ex-restructuring).
- Cash and investments $312.9M; repurchased 5.8M shares for $47.4M in Q1.
- Full-year 2025 revenue guidance reaffirmed: $250-$260M; net product sales guidance $240-$250M.
- Initial Phase 1 results for dual BAFF/APRIL inhibitor AUR200 expected later this quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062025000047/0001600620-25-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062025000047/auph-20250512.htm
  HTML page:      https://secwatch.observer/filing/0001600620-25-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer